A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Rui Shi
1, 2
,
Chao Shan
3
,
Xiaomin Duan
1, 2
,
Zhi-Hai Chen
4
,
Peipei Liu
5
,
Jin-Wen Song
6
,
Tao Song
1, 7, 8
,
Xiaoshan Bi
1, 9
,
Chao Han
1, 2
,
Lianao Wu
9, 10
,
Ge Gao
3
,
Xue Hu
3
,
Yanan Zhang
3
,
Tong Zhou
1, 10
,
Weijin Huang
11
,
William Jun Liu
5
,
Guizhen Wu
5
,
Bo Zhang
3
,
Lan Wang
11
,
Jianxun Qi
10, 12
,
Feng Hui
13
,
Fusheng Wang
6
,
Qihui Wang
1, 10, 12
,
George F. Gao
10
,
Zhiming Yuan
3
,
Jinghua Yan
1, 10, 12
4
7
Shanxi Academy of Advanced Research and Innovation, Taiyuan, China
|
13
Shanghai Junshi Biosciences Co. Ltd, Shanghai, China
|
Publication type: Journal Article
Publication date: 2020-05-26
scimago Q1
wos Q1
SJR: 18.288
CiteScore: 78.1
Impact factor: 48.5
ISSN: 00280836, 14764687
PubMed ID:
32454512
Multidisciplinary
Abstract
An outbreak of coronavirus disease 2019 (COVID-19)1–3, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4, has spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. Here we report the isolation of two specific human monoclonal antibodies (termed CA1 and CB6) from a patient convalescing from COVID-19. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro. In addition, CB6 inhibited infection with SARS-CoV-2 in rhesus monkeys in both prophylactic and treatment settings. We also performed structural studies, which revealed that CB6 recognizes an epitope that overlaps with angiotensin-converting enzyme 2 (ACE2)-binding sites in the SARS-CoV-2 receptor-binding domain, and thereby interferes with virus–receptor interactions by both steric hindrance and direct competition for interface residues. Our results suggest that CB6 deserves further study as a candidate for translation to the clinic. Two monoclonal antibodies isolated from a patient with COVID-19 are shown to interfere with SARS-CoV-2–receptor binding, and one displays potent action against this virus in vitro and in a rhesus macaque model.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
10
20
30
40
50
60
70
80
|
|
|
bioRxiv
76 publications, 5.93%
|
|
|
Nature Communications
40 publications, 3.12%
|
|
|
Frontiers in Immunology
34 publications, 2.65%
|
|
|
Cell Reports
27 publications, 2.11%
|
|
|
Cell
26 publications, 2.03%
|
|
|
Vaccines
21 publications, 1.64%
|
|
|
PLoS Pathogens
19 publications, 1.48%
|
|
|
Viruses
18 publications, 1.41%
|
|
|
Nature
18 publications, 1.41%
|
|
|
International Journal of Molecular Sciences
17 publications, 1.33%
|
|
|
Science
16 publications, 1.25%
|
|
|
Signal Transduction and Targeted Therapy
15 publications, 1.17%
|
|
|
Science Translational Medicine
14 publications, 1.09%
|
|
|
Emerging Microbes & Infections
14 publications, 1.09%
|
|
|
Scientific Reports
12 publications, 0.94%
|
|
|
Cell Host and Microbe
12 publications, 0.94%
|
|
|
iScience
10 publications, 0.78%
|
|
|
Cell Discovery
10 publications, 0.78%
|
|
|
Cell Reports Medicine
10 publications, 0.78%
|
|
|
Immunity
10 publications, 0.78%
|
|
|
medRxiv : the preprint server for health sciences
10 publications, 0.78%
|
|
|
mAbs
9 publications, 0.7%
|
|
|
Journal of Virology
9 publications, 0.7%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
9 publications, 0.7%
|
|
|
Frontiers in Microbiology
7 publications, 0.55%
|
|
|
Communications Biology
7 publications, 0.55%
|
|
|
Computational and Structural Biotechnology Journal
7 publications, 0.55%
|
|
|
Journal of Molecular Biology
7 publications, 0.55%
|
|
|
Microbiology spectrum
7 publications, 0.55%
|
|
|
10
20
30
40
50
60
70
80
|
Publishers
|
50
100
150
200
250
300
|
|
|
Cold Spring Harbor Laboratory
283 publications, 22.09%
|
|
|
Elsevier
257 publications, 20.06%
|
|
|
Springer Nature
209 publications, 16.32%
|
|
|
MDPI
96 publications, 7.49%
|
|
|
Frontiers Media S.A.
64 publications, 5%
|
|
|
Wiley
51 publications, 3.98%
|
|
|
American Chemical Society (ACS)
47 publications, 3.67%
|
|
|
Taylor & Francis
41 publications, 3.2%
|
|
|
American Association for the Advancement of Science (AAAS)
35 publications, 2.73%
|
|
|
Oxford University Press
32 publications, 2.5%
|
|
|
American Society for Microbiology
30 publications, 2.34%
|
|
|
Public Library of Science (PLoS)
28 publications, 2.19%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
9 publications, 0.7%
|
|
|
Royal Society of Chemistry (RSC)
8 publications, 0.62%
|
|
|
Rockefeller University Press
7 publications, 0.55%
|
|
|
American Society for Clinical Investigation
5 publications, 0.39%
|
|
|
American Society for Biochemistry and Molecular Biology
5 publications, 0.39%
|
|
|
Social Science Electronic Publishing
5 publications, 0.39%
|
|
|
Spandidos Publications
4 publications, 0.31%
|
|
|
European Molecular Biology Organization
4 publications, 0.31%
|
|
|
Bentham Science Publishers Ltd.
3 publications, 0.23%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 publications, 0.23%
|
|
|
Massachusetts Medical Society
2 publications, 0.16%
|
|
|
The American Association of Immunologists
2 publications, 0.16%
|
|
|
Mary Ann Liebert
2 publications, 0.16%
|
|
|
SAGE
2 publications, 0.16%
|
|
|
Hindawi Limited
2 publications, 0.16%
|
|
|
Annual Reviews
2 publications, 0.16%
|
|
|
IntechOpen
2 publications, 0.16%
|
|
|
50
100
150
200
250
300
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
1.3k
Total citations:
1282
Citations from 2024:
145
(11.32%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Shi R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 // Nature. 2020. Vol. 584. No. 7819. pp. 120-124.
GOST all authors (up to 50)
Copy
Shi R., Shan C., Duan X., Chen Z., Liu P., Song J., Song T., Bi X., Han C., Wu L., Gao G., Hu X., Zhang Y., Zhou T., Huang W., Liu W. J., Wu G., Zhang B., Wang L., Qi J., Hui F., Wang F., Wang Q., Gao G. F., Yuan Z., Yan J. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 // Nature. 2020. Vol. 584. No. 7819. pp. 120-124.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/s41586-020-2381-y
UR - https://doi.org/10.1038/s41586-020-2381-y
TI - A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
T2 - Nature
AU - Shi, Rui
AU - Shan, Chao
AU - Duan, Xiaomin
AU - Chen, Zhi-Hai
AU - Liu, Peipei
AU - Song, Jin-Wen
AU - Song, Tao
AU - Bi, Xiaoshan
AU - Han, Chao
AU - Wu, Lianao
AU - Gao, Ge
AU - Hu, Xue
AU - Zhang, Yanan
AU - Zhou, Tong
AU - Huang, Weijin
AU - Liu, William Jun
AU - Wu, Guizhen
AU - Zhang, Bo
AU - Wang, Lan
AU - Qi, Jianxun
AU - Hui, Feng
AU - Wang, Fusheng
AU - Wang, Qihui
AU - Gao, George F.
AU - Yuan, Zhiming
AU - Yan, Jinghua
PY - 2020
DA - 2020/05/26
PB - Springer Nature
SP - 120-124
IS - 7819
VL - 584
PMID - 32454512
SN - 0028-0836
SN - 1476-4687
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2020_Shi,
author = {Rui Shi and Chao Shan and Xiaomin Duan and Zhi-Hai Chen and Peipei Liu and Jin-Wen Song and Tao Song and Xiaoshan Bi and Chao Han and Lianao Wu and Ge Gao and Xue Hu and Yanan Zhang and Tong Zhou and Weijin Huang and William Jun Liu and Guizhen Wu and Bo Zhang and Lan Wang and Jianxun Qi and Feng Hui and Fusheng Wang and Qihui Wang and George F. Gao and Zhiming Yuan and Jinghua Yan},
title = {A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2},
journal = {Nature},
year = {2020},
volume = {584},
publisher = {Springer Nature},
month = {may},
url = {https://doi.org/10.1038/s41586-020-2381-y},
number = {7819},
pages = {120--124},
doi = {10.1038/s41586-020-2381-y}
}
Cite this
MLA
Copy
Shi, Rui, et al. “A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.” Nature, vol. 584, no. 7819, May. 2020, pp. 120-124. https://doi.org/10.1038/s41586-020-2381-y.